This article was originally published in The Gray Sheet
Requirement that patients demonstrate adaquate renal, hepatic, pulmonary and cardiac function in order to be eligible for national coverage for autologous stem cell transplantation (AuSCT) for multiple myeloma is sufficient, and HCFA will not reinstate a cut-off at age 77, the agency decides Feb. 9. Age was to serve as a proxy for predicting who would be susceptible to co-morbidities associated with the procedure; however, HCFA canceled the age restriction Oct. 1, 2000, saying it would try instead to identify specific co-morbidities through an internal review
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.